The authors declare that they have no competing interests.
Although typically a late feature of gout, tophi may present early in the course of disease. The aim of this study was to identify factors associated with the presence of early tophaceous disease.
People with gout for <10 years were prospectively recruited, and had a comprehensive clinical assessment including examination for subcutaneous tophi. The clinical factors independently associated with the presence and number of tophi were analyzed using regression models.
Of the 290 participants, there were 47 (16.2%) with clinically apparent tophi. In univariate analysis, those with tophi were older, were more frequently taking diuretics and colchicine prophylaxis, and had lower creatinine clearance. The association between the presence of tophi and creatinine clearance was strongest in those with creatinine clearance ≤30 ml/min. In logistic regression analysis, creatinine clearance ≤30 ml/min was associated with the presence of tophi, even after adjusting for ethnicity, corticosteroid use, colchicine use and diuretic use (multivariate adjusted odds ratio 7.0, p = 0.005). Participants with tophi reported higher frequency of gout flares, pain scores, patient global assessment scores, and HAQ scores.
The presence of tophi is associated with more symptomatic disease in people with gout for <10 years. Creatinine clearance is independently associated with early presentation of subcutaneous tophi.
Hench PS: The diagnosis of gout and gout arthritis. J Lab Clin Med. 1936, 22: 48-55.
Wordsworth BP, Mowat AG: Rapid development of gouty tophi after diuretic therapy. J Rheumatol. 1985, 12 (2): 376-377. PubMed
Baethge BA, Work J, Landreneau MD, McDonald JC: Tophaceous gout in patients with renal transplants treated with cyclosporine A. J Rheumatol. 1993, 20 (4): 718-720. PubMed
Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM: Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford). 2007, 46 (12): 1804-1807. 10.1093/rheumatology/kem246. CrossRef
Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D: Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes. 2012, 10: 117-10.1186/1477-7525-10-117. CrossRefPubMedPubMedCentral
Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM, Taylor WJ: Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken). 2011, 63 (11): 1605-1612. 10.1002/acr.20570. CrossRef
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: modification of diet in renal disease study group. Ann Intern Med. 1999, 130 (6): 461-470. 10.7326/0003-4819-130-6-199903160-00002. CrossRefPubMed
Schreiner O, Wandel E, Himmelsbach F, Galle PR, Marker-Hermann E: Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients?. Nephrol Dial Transplant. 2000, 15 (5): 644-649. 10.1093/ndt/15.5.644. CrossRefPubMed
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR: American college of rheumatology guidelines for management of gout: part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012, 64 (10): 1431-1446. 10.1002/acr.21772. CrossRef
Harrold LR, Mazor KM, Negron A, Ogarek J, Firneno C, Yood RA: Primary care providers’ knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford). 2013, 52 (9): 1623-1629. 10.1093/rheumatology/ket158. CrossRef
Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR: Progress in measurement instruments for acute and chronic gout studies. J Rheumatol. 2009, 36 (10): 2346-2355. 10.3899/jrheum.090371. CrossRefPubMed
- Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout
Meaghan E House
William J Taylor
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II